37656-48-7

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-(4-Fluoro-phenyl)-piperidine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique structure and properties. It aids in the design and development of novel drugs with potential therapeutic applications.
Used in Central Nervous System Applications:
In the field of neurology and psychiatry, 4-(4-Fluoro-phenyl)-piperidine is used as a potential analgesic and antipsychotic agent. Its interaction with the central nervous system positions it as a candidate for the treatment of pain and psychiatric disorders.
Used in the Development of Therapeutics for Neurological and Psychiatric Disorders:
4-(4-Fluoro-phenyl)-piperidine is employed as a starting point for the development of new therapeutics targeting a range of neurological and psychiatric conditions. Its potential in this area is attributed to its ability to modulate specific pathways and receptors within the central nervous system.

InChI:InChI=1/C11H14FN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2

Upstream product

• 1978-61-6 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 462-06-6 fluorobenzene 
• 7440-05-3 palladium 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 138647-52-6 4-(4-fluorophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 183950-95-0 tert-butyl 4-(4'-fluorophenyl)piperidine-1-carboxylate 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 1082659-96-8 4-(4-fluorophenyl) tetrahydro pyridine hydrochloride 
• 459-57-4 4-fluorobenzaldehyde 
• 3449-63-6 3-(4-fluorophenyl)pentan-1,5-dioic acid 
• 352-13-6 4-flourophenylmagnesium bromide 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 301220-43-9 (R)-Cyclohexyl-{(3S,4S)-3-[4-(4-fluoro-phenyl)-piperidin-1-ylmethyl]-4-phenyl-pyrrolidin-1-yl}-acetic acid benzyl ester 
• 691876-45-6 2-(2-tert-butoxycarbonylamino-thiazol-4-yl)-4-[4-(4-fluoro-phenyl)-piperidin-1-yl]-butyric acid ethyl ester 
• 771-99-3 4-phenylpiperidine 
• 180157-82-8 (2S)-(-)-1-(4-indolyloxy)-3-(4-(4-fluorophenyl)piperidin-1-yl)-2-propanol ethanedioate 
• 174775-82-7 1-(6-aminoindan-1-ylmethyl)-4-(4-fluorophenyl)piperidine 
• 1029643-97-7 C₂₁H₂₁FN₂O₂ 
• 1021205-50-4 C₂₅H₃₁FN₂O 

Relevant academic research and scientific papers

VMAT INHIBITORY COMPOUNDS

Disclosed herein are compounds that bind to the vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions comprising those compounds, and methods of treatment using said compounds and pharmaceutical compositions.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

1-[(1-methyl-1 H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis

A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.

ORGANIC COMPOUNDS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals (I) wherein R1 R2 R3, R4 and W are as defined herein.

ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY

Compounds of (I), or stereoisomers or pharmaceutically acceptable salts thereof, where W, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter

18F labelled vesamicol analogues, which bind to the vesicular acetylcholine transporter (VAChT) in central cholinergic nerve terminals, are expected to be potential radioligands for the visualisation of cholinergic transmission deficits via pos

Cyclohexyl derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

N-sulfonylurea apoptosis promoters

Compounds having the formula are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.